AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32708600 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair massage
Number of subjects: 44
Study 32708600 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 44
Study 32708600 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 616840383 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-He point group (puncturing at Zusanli (ST36))
Number of subjects: 105
Study 616840383 — intervention group
Group type: EXPERIMENTAL
Intervention: Mu point group (puncturing at Zhongwan (CV12))
Number of subjects: 105
Study 616840383 — intervention group
Group type: EXPERIMENTAL
Intervention: He-Mu point combination group (puncturing at ST36 and CV12)
Number of subjects: 105
Study 616840383 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 105
Study 35946229 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mobile phone usage
Number of subjects: 566
Study 33926591 — intervention group
Group type: EXPERIMENTAL
Intervention: PROTECT psychotherapy (N = 25)
Number of subjects: 40
Study 33926591 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (N = 15)
Number of subjects: 40
Study 32554566 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic decision support tool
Number of subjects: 3904
Study 32554566 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 3904
Study 33630475 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) chemotherapy and chemoradiation (N = 158)
Number of subjects: 303
Study 33630475 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPa immunotherapy combined with SOC chemotherapy and chemoradiation (N = 145)
Number of subjects: 303
Study 33799224 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingfei Paidu Tang (QPT)
Number of subjects: 8939
Study 33799224 — intervention group
Group type: COMPARATOR
Intervention: Not receiving QPT (Control)
Number of subjects: 8939
Study 34424307 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose HBV vaccination (3 doses of 40 μg recombinant hepatitis B vaccine at 0, 1, and 2 months)
Number of subjects: 107
Study 34424307 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose HBV vaccination (3 doses of 20 μg each at 0, 1, and 2 months)
Number of subjects: 107
Study 34424307 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose HBV vaccination
Number of subjects: 107
Study 34424307 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose HBV vaccination
Number of subjects: 107
Study 32456514 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care
Number of subjects: 1431
Study 35416101 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism Adaptation Training (PAT)
Number of subjects: 23
Study 32984946 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaprezinc (PZ) lozenge treatment started before chemotherapy
Number of subjects: 88
Study 32984946 — intervention group
Group type: COMPARATOR
Intervention: Control group (PZ lozenges initiated after onset of Grade 2 oral mucositis)
Number of subjects: 88
Study 32984946 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaprezinc (PZ) lozenge treatment
Number of subjects: 88
Study 32984946 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 32171499 — intervention group
Group type: EXPERIMENTAL
Intervention: ESP block with 20 mL of 0.5% ropivacaine bilaterally at T8 level
Number of subjects: 31
Study 32171499 — intervention group
Group type: COMPARATOR
Intervention: Epidural block with 20 mL of 0.5% ropivacaine and 1 mg of morphine at T8-T9 space
Number of subjects: 31
Study 32171499 — intervention group
Group type: EXPERIMENTAL
Intervention: ESP block
Number of subjects: 31
Study 32828115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (Tracleer®)
Number of subjects: 10
Study 32828115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 32985131 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Health Record (EHR) weight data
Number of subjects: 0
Study 32985131 — intervention group
Group type: COMPARATOR
Intervention: Primary trial weight data
Number of subjects: 0
Study 36331502 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip brace worn for at least 12 hours a day for 12 months
Number of subjects: 66
Study 36331502 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation therapy (control group)
Number of subjects: 66
Study 36331502 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip brace intervention
Number of subjects: 66
Study 33216012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 13
Study 33435326 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed formula with added 2′-FL
Number of subjects: 48
Study 33028335 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 473
Study 33028335 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping planning
Number of subjects: 473
Study 33028335 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of three BCTs (action planning, coping planning, self-monitoring)
Number of subjects: 473
Study 33028335 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of action planning and self-monitoring
Number of subjects: 473
Study 33028335 — intervention group
Group type: EXPERIMENTAL
Intervention: Action planning with coping planning
Number of subjects: 473
Study 33028335 — intervention group
Group type: EXPERIMENTAL
Intervention: Action planning alone
Number of subjects: 473
Study 34475156 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (10-20 mg/day)
Number of subjects: 156
Study 34475156 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (7.5-15 mg/day)
Number of subjects: 156
Study 34475156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 33081496 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure at admission
Number of subjects: 13172
Study 33459675 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 90
Study 33459675 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback postural training (BPT)
Number of subjects: 90
Study 33459675 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercises (Control)
Number of subjects: 90
Study 32485422 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Treatment A (intermittent vibrational cutaneous stimulation)
Number of subjects: 32
Study 32485422 — intervention group
Group type: COMPARATOR
Intervention: Passive Treatment B (no active stimulation)
Number of subjects: 32
Study 32485422 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Treatment A
Number of subjects: 32
Study 36149628 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 158
Study 36149628 — intervention group
Group type: COMPARATOR
Intervention: Combined intracervical foley’s catheter plus intravenous oxytocin infusion
Number of subjects: 158
Study 34011413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 mg tablet every other day for 2 months)
Number of subjects: 60
Study 34011413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical in terms of shape, color, and smell, every other day for 2 months)
Number of subjects: 60
Study 32764090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic-guided dual antiplatelet therapy (DAPT) with ticagrelor for high-risk patients
Number of subjects: 250
Study 32764090 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel treatment for low-risk patients
Number of subjects: 250
Study 35765086 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia with cryotherapy (TC)
Number of subjects: 80
Study 35765086 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia alone (T)
Number of subjects: 80
Study 33721611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg/day
Number of subjects: 346
Study 33721611 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib 250 mg/day
Number of subjects: 346
Study 35296791 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception lifestyle intervention
Number of subjects: 315
Study 32616069 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4-mg
Number of subjects: 0
Study 32616069 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2-mg
Number of subjects: 0
Study 32616069 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 32616069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32616069 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX
Number of subjects: 0
Study 32616069 — intervention group
Group type: COMPARATOR
Intervention: Placebo in RA-BUILD
Number of subjects: 0
Study 33835187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pararectus approach
Number of subjects: 8
Study 33835187 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 8
Study 33618120 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention over 16 weeks
Number of subjects: 15
Study 33038969 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Number of subjects: 0
Study 33038969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36608972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy plus a Memory Support Intervention
Number of subjects: 178
Study 36608972 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy-as-usual
Number of subjects: 178
Study 34078971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention during allo‐HSCT
Number of subjects: 47
Study 34078971 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional intervention)
Number of subjects: 47
Study 34078971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 47
Study 32935866 — intervention group
Group type: EXPERIMENTAL
Intervention: MR 200 mg/day
Number of subjects: 66
Study 32935866 — intervention group
Group type: EXPERIMENTAL
Intervention: MR 400 mg/day
Number of subjects: 66
Study 32935866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 36325947 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Number of subjects: 100
Study 36325947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33351540 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid-CR (telehealth sessions)
Number of subjects: 47
Study 33351540 — intervention group
Group type: COMPARATOR
Intervention: Standard Cardiac Rehabilitation (S-CR)
Number of subjects: 47
Study 32928659 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily
Number of subjects: 1368
Study 32928659 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg twice daily
Number of subjects: 1368
Study 32928659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1368
Study 34451976 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1 vaccine combined with annual influenza vaccine
Number of subjects: 846
Study 34451976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 846
Study 32969518 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirm Rx
Number of subjects: 142
Study 32969518 — intervention group
Group type: COMPARATOR
Intervention: Reveal LINQ
Number of subjects: 142
Study 36438071 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (140 mg every 8 hours for 4 weeks)
Number of subjects: 56
Study 36438071 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same tablet shape, same dosage as silymarin)
Number of subjects: 56
Study 36438071 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 56
Study 33435878 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer-supported outdoor walking intervention (30-50 minutes, three times a week for 6 months)
Number of subjects: 0
Study 33435878 — intervention group
Group type: COMPARATOR
Intervention: Control group (two lectures covering health-related topics)
Number of subjects: 0
Study 33435878 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer-supported outdoor walking intervention
Number of subjects: 0
Study 35229613 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (1 week dosing)
Number of subjects: 102
Study 35229613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 35229613 — intervention group
Group type: EXPERIMENTAL
Intervention: PXR agonist dosing in rats (6 days)
Number of subjects: 102
Study 35229613 — intervention group
Group type: COMPARATOR
Intervention: PXR agonist (withdrawn)
Number of subjects: 102
Study 35229613 — intervention group
Group type: EXPERIMENTAL
Intervention: 4βHC
Number of subjects: 102
Study 35219144 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm and sexual obsession induction paradigms
Number of subjects: 55
Study 35219144 — intervention group
Group type: EXPERIMENTAL
Intervention: Shame responses
Number of subjects: 55
Study 33773170 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Chinese medicine
Number of subjects: 0
Study 33773170 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 34345805 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart About Meds (SAM) mobile application
Number of subjects: 49
Study 34345805 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 49
Study 33393835 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 411
Study 33393835 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 411
Study 33393835 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg (EM from placebo-controlled trial)
Number of subjects: 411
Study 33393835 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg (EM from placebo-controlled trial)
Number of subjects: 411
Study 33393835 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg (CM)
Number of subjects: 411
Study 33393835 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg (CM)
Number of subjects: 411
Study 33393835 — intervention group
Group type: COMPARATOR
Intervention: Placebo (previously in double-blind trial)
Number of subjects: 411
Study 35262315 — intervention group
Group type: EXPERIMENTAL
Intervention: Social learning group (SoLG) observing positive treatment outcomes in a sham patient
Number of subjects: 44
Study 35262315 — intervention group
Group type: COMPARATOR
Intervention: Control group hearing neutral effects from the sham patient
Number of subjects: 44
Study 33302884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephone management (NLTM)
Number of subjects: 1154
Study 33302884 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1154
Study 34051076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus buchneri 40788 and Pediococcus pentocaseus 12455 (LBPP)
Number of subjects: 0
Study 34051076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate, potassium sorbate, and sodium nitrite (SFE)
Number of subjects: 0
Study 34051076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum MTD1 (LP)
Number of subjects: 0
Study 34051076 — intervention group
Group type: COMPARATOR
Intervention: Untreated (CTRL)
Number of subjects: 0
Study 32101336 — intervention group
Group type: EXPERIMENTAL
Intervention: Woman-picked Peak Day
Number of subjects: 57
Study 32101336 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert-picked Peak Day
Number of subjects: 57
Study 32101336 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-picked Peak Day
Number of subjects: 57
Study 34779154 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Nephrectomy (PN)
Number of subjects: 3196
Study 34779154 — intervention group
Group type: COMPARATOR
Intervention: Radical Nephrectomy (RN)
Number of subjects: 3196
Study 32041664 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent-friendly services (AFS) utilization
Number of subjects: 362
Study 32041664 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors positively associated with AFS utilization
Number of subjects: 362
Study 32041664 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative factors affecting AFS utilization
Number of subjects: 362
Study 35913836 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 82
Study 35913836 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Number of subjects: 82
Study 35913836 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 82
Study 34081233 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI at 36.5 h post HCG and/or Lupron trigger
Number of subjects: 12
Study 34081233 — intervention group
Group type: COMPARATOR
Intervention: ICSI at 39 h post HCG and/or Lupron trigger
Number of subjects: 12
Study 32061002 — intervention group
Group type: EXPERIMENTAL
Intervention: Low radiation dose contrast‐enhanced mammography (L‐CEM)
Number of subjects: 80
Study 32061002 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced MRI (CE‐MRI)
Number of subjects: 80
Study 36348309 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded activity receiving cognitive-behavioral therapy (GA)
Number of subjects: 180
Study 36348309 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group-based combined exercise therapy and education (SET)
Number of subjects: 180
Study 36348309 — intervention group
Group type: COMPARATOR
Intervention: Graded activity (GA)
Number of subjects: 180
Study 36348309 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise therapy (SET)
Number of subjects: 180
Study 33315489 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed prasugrel tablets (60 mg loading dose)
Number of subjects: 727
Study 33315489 — intervention group
Group type: COMPARATOR
Intervention: Integral prasugrel tablets (60 mg loading dose)
Number of subjects: 727
Study 36054089 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg daily)
Number of subjects: 20
Study 36054089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 33142248 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based data visualization tool for reviewing de-identified anesthesia records
Number of subjects: 19
Study 33142248 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 19
Study 33142248 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent assessments with the tool
Number of subjects: 19
Study 32399130 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Zhongwan (CV 12) and Zusanli (ST 36)
Number of subjects: 99
Study 32399130 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6) and Zusanli (ST 36)
Number of subjects: 99
Study 32399130 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at nonacupoint and Zusanli (ST 36)
Number of subjects: 99
Study 32399130 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 99
Study 35697297 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-off technique
Number of subjects: 70
Study 35697297 — intervention group
Group type: COMPARATOR
Intervention: Hands-on technique (Control)
Number of subjects: 70
Study 32770222 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic warning labels with 'US Food and Drug Administration' sponsorship
Number of subjects: 487
Study 32770222 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic warning labels with 'American Cancer Society' sponsorship
Number of subjects: 487
Study 32770222 — intervention group
Group type: COMPARATOR
Intervention: Graphic warning labels with no sponsor
Number of subjects: 487
Study 35695680 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive language facilitation strategies
Number of subjects: 0
Study 35695680 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive language facilitation strategies
Number of subjects: 0
Study 35695680 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-mediated intervention
Number of subjects: 0
Study 35695680 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching mothers to use responsive strategies
Number of subjects: 0
Study 34197268 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medications
Number of subjects: 175
Study 34197268 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medications in ATC groups N05/N06A
Number of subjects: 175
Study 34197268 — intervention group
Group type: EXPERIMENTAL
Intervention: Beers Criteria
Number of subjects: 175
Study 32871662 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Training (IT)
Number of subjects: 62
Study 32871662 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized Training (GT)
Number of subjects: 62
Study 32871662 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 62
Study 36200450 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0
Study 36200450 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Continuous Exercise Training
Number of subjects: 0
Study 36200450 — intervention group
Group type: COMPARATOR
Intervention: Control group (guideline based advice for ET)
Number of subjects: 0
Study 33210285 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (20 units)
Number of subjects: 60
Study 33210285 — intervention group
Group type: COMPARATOR
Intervention: Control (20 cc normal saline)
Number of subjects: 60
Study 33198235 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-rich diets containing fresh fruits, nuts, seeds, and peanuts
Number of subjects: 226
Study 33198235 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal product-rich diets
Number of subjects: 226
Study 33198235 — intervention group
Group type: COMPARATOR
Intervention: Cognition
Number of subjects: 226
Study 34954933 — intervention group
Group type: EXPERIMENTAL
Intervention: BM-PIOMI
Number of subjects: 68
Study 33121714 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4330
Study 33121714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4330
Study 33121714 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NT-proBNP ≥125 pg/ml
Number of subjects: 4330